Annual Review | Dr. Kan Gong: Advances in the Diagnosis and Treatment of Localized Prostate Cancer in 2024

Annual Review | Dr. Kan Gong: Advances in the Diagnosis and Treatment of Localized Prostate Cancer in 2024

2025.02.11
Prostate cancer is one of the most common malignancies threatening men's health worldwide. With population aging and lifestyle changes, the incidence of prostate cancer in China has been steadily increasing in recent years. As an early-stage disease, localized prostate cancer generally has a favorable prognosis, with curative potential through comprehensive treatment primarily centered on local interventions such as surgery. Enhancing the diagnosis and treatment of localized prostate cancer is key to improving overall survival rates for prostate cancer patients. Looking back at 2024, what were the major research advances in this field? This review will summarize key developments in screening and diagnosis, neoadjuvant therapy, surgical treatment, and the management of biochemical recurrence after surgery.
Annual Review | Addressing Unmet Needs: Dr. Qiang Wei on Advances in Bladder Cancer Treatment in 2024

Annual Review | Addressing Unmet Needs: Dr. Qiang Wei on Advances in Bladder Cancer Treatment in 2024

2025.02.11
Bladder cancer is one of the most common malignancies of the urinary system, posing a serious threat to public health in China. For patients with localized disease, repeated intravesical treatments and follow-up procedures require frequent hospital visits, while those who undergo surgery often face the lifelong challenge of urinary diversion. Patients with inoperable advanced bladder cancer also have limited treatment options, as traditional chemotherapy provides only modest benefits. These significant unmet medical needs—affecting both survival and quality of life—have driven continuous innovation in the field of bladder cancer treatment.

Dr. Yaping Yang: Characteristics and Personalized Treatment Strategies for Young Breast Cancer Patients | 2024 Yixian Breast Cancer Conference

2025.02.10
Editorial Note: The 2024 Yixian Breast Cancer Conference and the 2nd China Young Breast Cancer Consensus Conference, held on December 27–28 in Guangzhou, focused on cutting-edge topics such as the changing epidemiology of young breast cancer, screening strategies, the impact of genetic mutations, treatment, and rehabilitation. During the conference, Dr. Yaping Yang from Sun Yat-sen Memorial Hospital delivered a lecture on “Genetic Mutations in Young Breast Cancer Patients,” addressing key issues such as the impact of genetic mutations on cure rates and whether routine referrals to breast specialists are necessary for BRCA-mutated ovarian cancer patients. In an interview with Oncology Frontier, Professor Yang discussed the characteristics of young breast cancer patients and provided personalized treatment recommendations for those carrying genetic mutations.
Annual Review | Dr. Xiaofan Zhu: Advances in Pediatric ALL and AML in 2024

Annual Review | Dr. Xiaofan Zhu: Advances in Pediatric ALL and AML in 2024

2025.02.10
In 2024, significant progress was made in the field of pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), bringing new insights and advancements to clinical practice. These studies covered innovations in treatment approaches, evaluations of drug efficacy, and a deeper understanding of the biological characteristics of these diseases. These findings are crucial for advancing precision medicine in pediatric leukemia and improving patient outcomes.